Literature DB >> 18166790

Hepcidin: from discovery to differential diagnosis.

Erwin H J M Kemna1, Harold Tjalsma, Hans L Willems, Dorine W Swinkels.   

Abstract

Although iron is essential for living organisms to survive, its reactive properties require strict regulation in order to prevent toxic effects. Hepcidin, a liver produced peptide hormone, is thought to be the central regulator of body iron metabolism. Its production is mainly controlled by the erythropoietic activity of the bone-marrow, the amount of circulating and stored body iron, and inflammation. Recent reports, however, provide new hypotheses on how hepcidin might exert its regulatory function. Although hepcidin was first discovered in human urine and serum, most of our understanding of hepcidin regulation and action comes from in vitro and mice studies that often use hepcidin mRNA expression as a read out. The difficulties in carrying out studies in humans have mostly been due to the lack of suitable hepcidin assay. The recent development of assays to measure hepcidin in serum and urine has offered new opportunities to study hepcidin regulation in humans. However, for the moment, only a small number of laboratories are able to perform these assays. The aim of this review is to discuss insights into hepcidin regulation obtained from recent clinical studies in the light of findings from in vitro and mice studies. Ongoing studies in humans should provide us with more information on the etiology of iron metabolism disorders in order to create new therapeutic strategies and improve differential diagnosis protocols for these diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18166790     DOI: 10.3324/haematol.11705

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  76 in total

1.  Rescuing iron-overloaded macrophages by conservative relocation of the accumulated metal.

Authors:  Yang-Sung Sohn; Anna-Maria Mitterstiller; William Breuer; Guenter Weiss; Z Ioav Cabantchik
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

2.  Regulation of serum hepcidin levels in sickle cell disease.

Authors:  Joyce J C Kroot; Coby M M Laarakkers; Erwin H J M Kemna; Bart J Biemond; Dorine W Swinkels
Journal:  Haematologica       Date:  2009-06       Impact factor: 9.941

3.  Immunoassay-based serum hepcidin reference range measurements in healthy children: differences among age groups.

Authors:  Triantafyllia Sdogou; Charalampos Tsentidis; Dimitrios Gourgiotis; Antonios Marmarinos; Alexandra Gkourogianni; Ioannis Papassotiriou; Theodora Anastasiou; Lydia Kossiva
Journal:  J Clin Lab Anal       Date:  2014-03-22       Impact factor: 2.352

Review 4.  Management of Anemia in Patients with Inflammatory Bowel Disease (IBD).

Authors:  Dhruvan Patel; Chinmay Trivedi; Nabeel Khan
Journal:  Curr Treat Options Gastroenterol       Date:  2018-03

Review 5.  Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease.

Authors:  Elena Canavesi; Carlo Alfieri; Serena Pelusi; Luca Valenti
Journal:  World J Nephrol       Date:  2012-12-06

6.  Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.

Authors:  Keitaro Yokoyama; Hideki Hirakata; Takashi Akiba; Masafumi Fukagawa; Masaaki Nakayama; Kenichi Sawada; Yuji Kumagai; Geoffrey A Block
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-09       Impact factor: 8.237

7.  Impact of graphene-based nanomaterials (GBNMs) on the structural and functional conformations of hepcidin peptide.

Authors:  Krishna P Singh; Lokesh Baweja; Olaf Wolkenhauer; Qamar Rahman; Shailendra K Gupta
Journal:  J Comput Aided Mol Des       Date:  2018-02-03       Impact factor: 3.686

Review 8.  Individualized treatment for iron-deficiency anemia in adults.

Authors:  Michael Alleyne; McDonald K Horne; Jeffery L Miller
Journal:  Am J Med       Date:  2008-11       Impact factor: 4.965

9.  Effects of additional iron doses on hepcidin-25 level in hemodialysis patients without evident iron deficiency.

Authors:  Lavinia Oltiţa Brătescu; Liliana Bârsan; Liliana Gârneaţă; Ana Stanciu; Mariana Lipan; Simona Hildegard Stancu; Gabriel Mircescu
Journal:  Int Urol Nephrol       Date:  2014-03-29       Impact factor: 2.370

10.  Time-course analysis of serum hepcidin, iron and cytokines in a C282Y homozygous patient with Schnitzler's syndrome treated with IL-1 receptor antagonist.

Authors:  Marcel van Deuren; Joyce J C Kroot; Dorine W Swinkels
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.